Epstein Secrets

the presence or absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics) PSA, FREE 0.33 Not Estab. ng/mL I 0.31 10/27/201S BioReference Laboratories, Inc. Elmwood Park, NJ 07407 James Weisberger M.D. Page 3 of S Laboratory Director Prin

10/27/2015 MCHC 34.6 29.0-35.0 gm/dL 34.8 10/27/2015 RDW 13.9 10.9-16.9 % 14.4 10/27/2015 POLYS 49.2 36.0-78.0 % 51.1 10/27/2015 LYMPHS 36.2 12.0-48.0 % 37.1 10/27/2015 MONOS 7.6 0.0-13.0 5.8 10/27/2015 COS 6.5 0.0-8.0 % 5.4 10/27/2015 BASOS 0.4 0.0-2.0 % 0.6 10/

th different assay methods or kits cannot be interchangeably. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). Not Estab. ng/mL to moderate or marked of the obtained used I 0.33 ¶01/27/2016 % FREE PSA TNP FREE PSA RISK ASSESSMENT The probability of prostate

1/27/2016 MCHC 35.2 MI 29.0-35.0 gm/dL 34.6 01/27/2016 ROW 14.8 10.9-16.9 % 13.9 01/27/2016 POLYS 45.8 36.0-78.0 % 49.2 01/27/2016 LYMPHS 39.0 12.0-48.0 X 36.2 01/27/2016 MONOS 8.9 0.0-13.0 % 7.6 01/27/2016 EOS 5.4 0.0-8.0 % 6.5 01/27/2016 BASOS 0.6 0.0-2.0 % 0.4

th different assay methods or kits cannot be interchangeably. ASSAY INFORMATION: Method Electrocheedluninescence Immunoassay (Roche Diagnostics). Not Estab. ng/mi. to moderate or marked of the obtained used 1 0.33 101/27/2016 % FREE PSA TNP FREE PSA RISK ASSESSMENT The probability of prostate

1/27/2016 MCHC 35.2 HI 29.0-35.0 ge/dL 34.6 01/27/2016 ROW 14.8 10.9-16.9 % 13.9 01/27/2016 POLYS 45.8 36.0-78.0 % 49.2 01/27/2016 LYMPHS 39.0 12.0-48.0 % 36.2 01/27/2016 MONOS 6.9 0.0-13.0 % 7.6 01/27/2016 EOS 5.4 0.0-8.0 % 6.5 01/27/2016 BASOS 0.6 0.0-2.0 % 0.4